You can always get back in Clapper. Start small and keep dry powder. This stock gives you plenty of opportunities. Who said you can''t change your mind?
Actually atty is probably the biggest looser on this board. he dropped out at around 40 just as it was about to go up and probably regrets ever since. In any case I agree with you after such a long time of frustration when you finally gained up a bit you said enough is enough . I too said to myself , at 50 I will leave but just cannot get myself to do it yet. I just dont feel I have any better options right now with the money although I keep fearing that the whole market might be a little too high. In any case good luck to you and hope to see you again :-).
Lovastatin is made from fermented aspergillus terreus, a fungus. Anybody ever track how many patients died of heart attacks while taking these drugs?
The next 3 days should tell all. Run up to earnings then.... what do you think board. My guess is that we hit 52 week high then maybe stall. Hoping $55 becomes support with a good report and guidance but willing to swing trade again if we drop below $50. GLTA
actually from what I remember , the stock usually went down the past few earning reports. seems that the expectations are always a little higher then the actual report itself. I really hope this time it will be different , the stock has been up the past few days with no apparent reason .
I agree with your post blue. We did not hit the 52 wk high today, but close. maybe another run at it tomorrow, then like you and clap both said beat has been underwhelming (.52%) last quarters and stock has fallen. I think one stat in the call will be a possible catalyst. they have managed to switch 50% of patients to new patent protected copaxone and there is still no ok from fda for generic. will not last forever but in the meantime big $ for teva. GLTA
Revenues of $5.1 billion, in line with the third quarter of 2013. Excluding the impact of the divestment of the U.S. OTC plants and of foreign exchange fluctuations, sales grew organically by 2%. Non-GAAP operating income of $1.5 billion, an increase of 13% from the third quarter of 2013. GAAP operating income of $1.1 billion, up 39%. Non-GAAP net income of $1.1 billion, an increase of 6%. GAAP net incomeof $876 million, up 23%. Non-GAAP diluted EPS of $1.32, an increase of 4%. GAAP diluted EPS of $1.02, up 21%. Strong cash flow from operations of $1.4 billion, an increase of over 200% compared to the third quarter of 2013. Generic medicine profitability improved 40% to reach $556 million. EPS guidance for full-year 2014 raised to $5.00-5.10, from $4.90-5.10. Company increases its share repurchase program to $3 billion, with purchases to commence promptly; represents an increase of $1.7 billion to the existing program
Looks excellent , Long time since we got such a possitive report. just hope the general atmosphere of the red markets today wont influence this good news too much .
Update: InvenSense Q2 Earnings - Margin Pressure Overshadows Top-Line Growth
Oct. 29, 2014 9:51 AM ET | 5 comments | About: InvenSense (INVN)
Disclosure: The author has no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. (More...)
InvenSense registered 27% year-over-year revenue growth, but earnings declined 37% sequentially. Revenue was almost in line, but the company missed EPS consensus by $0.11. Stock was down 25% in after-hours.
This creates a buying opportunity as the stock is now trading reasonably on forward PE basis.
Margin pressure was anticipated in the initiation report and the sell call benefited investors.
InvenSense (NYSE:INVN), a MEMS company, recently reported results of its second fiscal quarter of 2015. Revenue was around $90.2 million, up 35% sequentially and 27% on a year-over-year basis. Revenue came almost in line with expectations as Wall Street was modeling for $90.48 million for the quarter. InvenSense posted non-GAAP EPS of $0.05 as compared to $0.21 during the same quarter last year, translating into a 76% decline on a year-over-year basis. Earnings also declined by 37% on sequential basis. InvenSense missed Wall Street estimates by $0.11. The company is guiding for third-quarter revenue of $108 million-$115 million and EPS of $0.17-$0.21, mostly below the consensus of $116.3 million and $0.30, respectively. Shares were down 24% in the after hours trading. A recent piece mentioned that InvenSense can be quite sensitive to negative earnings result.
This article was sent to 12,763 people who get email alerts on INVN.
Get email alerts on INVN »
This result was not expected by most analysts. Most of them didn't see inventory build-up and margin pressure coming. Gross margin, non-GAAP, of the company was 37% as compared to 50% in the first fiscal quarter of 2015. According to the company's management, an inventory charge related to earlier generation of the company's products resulted in an 8% decline in gross margin. Further, revenue mix also shifted towards a low-margin, high-volume customer - we all know who that is. InvenSense's business with Apple (NASDAQ:AAPL) put negative pressure, 5% to be precise, on the earnings of the company amid lower margin. On second thought, this low-margin customer can be Xiaomi, which makes up around 10% of InvenSense's sales. On a year-over-year basis, growth in R&D also contributed towards the earnings decline. R&D expenses more than doubled on a year-over-year basis. However, the management is confident and notes that "As we move beyond the second quarter's inventory adjustment, we believe that our solid business model will allow us to drive improved earnings leverage and shareholder return in the coming quarters." To review, top-line growth of the company is intact, but the bottom line is severely affected in the quarter, thanks to obsolete inventory and Apple. Declining ASP will continue to pressure earnings, and it was pointed out in the initiation report. However, inventory problem was nonrecurring and the company can return towards profitability in the third-quarter of fiscal 2015.
InvenSense will continue to feel margin pressure because of customers like Apple, which have the power to govern negotiations. Further, OEMs like Xiaomi simply can't pay higher rates as they compete in price sensitive markets. However, as the stock fell by around 24%, it seems cheap on PE basis. Investors should consider this as a buying opportunity. But caution should be exercised in frequent trading as the stock is highly volatile right now. Further, if the stock moves past $20, investors should avoid further buying.
Coverage was initiated with "InvenSense: Time To Get Defensive"